140 related articles for article (PubMed ID: 820673)
41. Immunological adjuvants in cancer immunotherapy.
Baldwin RW
Dev Biol Stand; 1977 Apr 13-15; 38():3-12. PubMed ID: 344097
[No Abstract] [Full Text] [Related]
42. Eradication by active specific immunotherapy of established tumor transplants and microscopic lymph node metastases.
Yarkoni E; Ashley MP; Zbar B; Sugimoto T; Rapp HJ
Cancer Res; 1982 Jul; 42(7):2544-6. PubMed ID: 7083146
[TBL] [Abstract][Full Text] [Related]
43. Radiation therapy and immunotherapy: the value of immunotherapy in the control of local and regional cancer.
Cancer; 1976 Apr; 37(4 Suppl):2108-19. PubMed ID: 769945
[No Abstract] [Full Text] [Related]
44. Nonspecific immunotherapy of malignant tumors.
Milas L; Withers HR
Radiology; 1976 Jan; 118(1):211-8. PubMed ID: 1105663
[TBL] [Abstract][Full Text] [Related]
45. BCG in cancer immunotherapy: experimental and clinical trials of its use in treatment of leukemia minimal and or residual disease.
Mathé G; Weiner R; Pouillart P; Schwarzenberg L; Jasmin C; Schneider M; Hayat M; Amiel JL; de Vassal F; Rosenfeld C
Natl Cancer Inst Monogr; 1973 Dec; 39():165-75. PubMed ID: 4595314
[No Abstract] [Full Text] [Related]
46. Effects of the methanol extraction residue (MER) tubercle bacillus fraction on the production of antibodies in vitro. III. Consequence of prior sensitization to MER.
Halperin D; Reuben C; Ben-Efraim S; Grover N; Weiss DW
Cell Immunol; 1985 May; 92(2):404-13. PubMed ID: 3922630
[TBL] [Abstract][Full Text] [Related]
47. The cellular and molecular basis of immunity against mycobacterial diseases.
Colston MJ
Soc Appl Bacteriol Symp Ser; 1996; 25():33S-39S. PubMed ID: 8972118
[No Abstract] [Full Text] [Related]
48. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
49. Antigen 85C on Mycobacterium bovis, BCG and M. tuberculosis promotes monocyte-CR3-mediated uptake of microbeads coated with mycobacterial products.
Hetland G; Wiker HG
Immunology; 1994 Jul; 82(3):445-9. PubMed ID: 7959881
[TBL] [Abstract][Full Text] [Related]
50. Molecular cloning and immunologic reactivity of a novel low molecular mass antigen of Mycobacterium tuberculosis.
Coler RN; Skeiky YA; Vedvick T; Bement T; Ovendale P; Campos-Neto A; Alderson MR; Reed SG
J Immunol; 1998 Sep; 161(5):2356-64. PubMed ID: 9725231
[TBL] [Abstract][Full Text] [Related]
51. In vitro measurement of protective mycobacterial immunity: antigen-specific expansion of T cells capable of inhibiting intracellular growth of bacille Calmette-Guérin.
Worku S; Hoft DF
Clin Infect Dis; 2000 Jun; 30 Suppl 3():S257-61. PubMed ID: 10875795
[TBL] [Abstract][Full Text] [Related]
52. Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis.
Aldwell FE; Cross ML; Fitzpatrick CE; Lambeth MR; de Lisle GW; Buddle BM
Vaccine; 2006 Mar; 24(12):2071-8. PubMed ID: 16332403
[TBL] [Abstract][Full Text] [Related]
53. Effects of the methanol extract residue (MER) tubercle bacillus fraction on the production of antibodies in vitro. II. Effects on macrophage and lymphocyte populations.
Ben-Efraim S; Halperin D; Reuben C; Dar O; Weiss DW
Cell Immunol; 1984 Jun; 86(1):33-45. PubMed ID: 6373023
[TBL] [Abstract][Full Text] [Related]
54. Bacillus Calmette-Guérin and antilymphocyte serum in carcinogenesis. Effects on the hamster pouch.
Giunta JL; Reif AE; Shklar G
Arch Pathol; 1974 Oct; 98(4):237-40. PubMed ID: 4606260
[No Abstract] [Full Text] [Related]
55. Bacillus Calmette-Guerin, Mycobacterium bovis, as an immunomodulator in atopic diseases.
Barlan I; Bahceciler NN; Akdis M; Akdis CA
Immunol Allergy Clin North Am; 2006 May; 26(2):365-77, ix. PubMed ID: 16701150
[TBL] [Abstract][Full Text] [Related]
56. Induction of cutaneous plasma cell tumor as a complication of adjuvant immunotherapy with methanol extraction residue of bacillus Calmette-Guérin.
Suster SM; Ronnen M; Huszar M; Pines A; Schibi-Brilliant G
Oncology; 1987; 44(5):279-82. PubMed ID: 3670794
[TBL] [Abstract][Full Text] [Related]
57. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis.
Feng CG; Palendira U; Demangel C; Spratt JM; Malin AS; Britton WJ
Infect Immun; 2001 Jun; 69(6):4174-6. PubMed ID: 11349095
[TBL] [Abstract][Full Text] [Related]
58. Frequency of IFN-gamma producing cells correlates with adjuvant enhancement of bacille Calmette-Guèrin induced protection against Mycobacterium bovis.
Logan KE; Chambers MA; Hewinson RG; Hogarth PJ
Vaccine; 2005 Dec; 23(48-49):5526-32. PubMed ID: 16105710
[TBL] [Abstract][Full Text] [Related]
59. Mitogenic and adjuvant activity of a methanol extraction residue (MER) of tubercle bacilli on mouse lymphoid cells in vitro.
Ben-Efraim S; Diamantstein T
Immunol Commun; 1975; 4(6):565-77. PubMed ID: 770312
[TBL] [Abstract][Full Text] [Related]
60. Immunotherapy with neuraminidase-treated cells and bacillus Calmette-Guerin.
Kollmorgen GM; Killion JJ; Sansing WA; Cantrell JL; Bundren JC; LeFever AV
Surgery; 1976 Feb; 79(02):202-8. PubMed ID: 1108258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
